drugset / Trial / NCT00068510
Vaccine Therapy in Treating Patients With Malignant Glioma
Phase 1
Completed
28 enrolled
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with malignant glioma.
Timeline
- Start
- 2003-06
- Primary completion
- 2012-09
- Completion
- 2012-09
Publications
- Results Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 1;11(15):5515-25. doi: 10.1158/1078-0432.CCR-05-0464.
- Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother. 2013 Feb;36(2):152-7. doi: 10.1097/CJI.0b013e3182811ae4.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | autologous tumor lysate-pulsed DC | Cell therapy | 1e+06 cells | Intramuscular |
| Subject | autologous tumor lysate-pulsed DC | Cell therapy | 5e+06 cells | Intramuscular |
| Subject | autologous tumor lysate-pulsed DC | Cell therapy | 1e+07 cells | Intramuscular |